Debate: Heparin Should be the First-line Therapy for Patients with ACS/ AMI - A. Michael Lincoff, MD

↳ This is a section part of Moment: CRT 2016 Coronary - The Thrombin Inhibitors Great Debate: Bivailrudin vs. Heparin

Add this Moment to your Passport

Learn from this moment and keep it forever.
add to passport
$3.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

Summary

Debate: Heparin Should be the First-line Therapy for Patients with ACS/ AMI presented by A. Michael Lincoff, MD at CRT 2016

Add this Moment to your Passport

Learn from this moment and keep it forever.
add to passport
$3.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

  • Interventional Cardiologists
  • Interventional Fellows

Session Name: The Thrombin Inhibitors Great Debate: Bivailrudin vs. Heparin

Track: Coronary

Learning Objectives

  • Update in advances in ACS & AMI Management

Other Components in this Moment

Overview
Debate: Is Bivalirudin Superior to Heparin for ACS Patients? - Gregg Stone, MD, FSCAI
Debate: Heparin Should be the First-line Therapy for Patients with ACS/ AMI - A. Michael Lincoff, MD
Loading Simple Education